Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03317730 · ClinicalTrials.gov registry record · Early Phase 1
Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer
A Early Phase 1 study of Locally Advanced Head and Neck Cancer, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 28
- Enrollment target
- 1
- Study location
NCT03317730: Completed Early Phase 1 study of Locally Advanced Head and Neck Cancer, sponsored by University of Alabama at Birmingham.
NCT03317730 is a Early Phase 1 study of Locally Advanced Head and Neck Cancer that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 28 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (47% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03317730, a Early Phase 1 study of Locally Advanced Head and Neck Cancer, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 28 participants
- Enrollment target
- 1
- Study location
Study Summary
To confirm the feasibility of studying Xtampza ER during radiotherapy (RT) for LAHNC as part of a prospective clinical trial.
Primary Outcome
Feasibility of administering Xtampza ER during RT is defined as continuation of the medication throughout RT. The number of patients who discontinue Xtampza ER due to difficulty with administration, perceived inefficacy, or toxicity will be recorded.
Conditions Studied
Interventions
- DRUG Xtampza ER
Study Locations (1)
Alabama
- Hazelrig-Salter Radiation Oncology Center - Birmingham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2018-05-01 |
| Est. Completion | 2020-11-17 |
| Phase | Early Phase 1 |
What the finished NCT03317730 record still lists
NCT03317730 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 28 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (47% lower).
The record links to 1 condition, with Locally Advanced Head and Neck Cancer appearing as the primary indexed condition, and to 1 intervention - of which Xtampza ER is the first listed.
NCT03317730 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT03317730 about?
NCT03317730 is a clinical study titled "Pilot Trial of Microsphere Oxycodone (Xtampza ER) for Pain Management in Patients Receiving Radiotherapy for Locally Advanced Head and Neck Cancer". To confirm the feasibility of studying Xtampza ER during radiotherapy (RT) for LAHNC as part of a prospective clinical trial.
What is the current status of trial NCT03317730?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 28 participants. The study started on 2018-05-01. Estimated completion is 2020-11-17.
What conditions does trial NCT03317730 study?
This clinical trial studies the following conditions: Locally Advanced Head and Neck Cancer.
What interventions are being tested in trial NCT03317730?
The interventions under investigation include: Xtampza ER (DRUG).
Who is sponsoring clinical trial NCT03317730?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03317730 being conducted?
This trial has 1 study location across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Locally Advanced Head and Neck Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03317730's enrollment target sits among peer trials
28 938th of 2000 higher than 1,039 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03471117 · 28 participants · Phase 4
Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients
- NCT03523975 · 28 participants · Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma
- NCT03608631 · 28 participants · Phase 1
iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation
- NCT03810651 · 28 participants · Early Phase 1
Pencil Beam Scanning in Patients With Renal Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI